Weight-loss drugs may prevent thousands of knee replacements, study suggests

New research suggests that the use of weight-loss medications for a period of at least three years could potentially prevent thousands of knee replacement surgeries annually. This finding highlights a possible new intersection between metabolic health and joint preservation.

The Scale of the Osteoarthritis Challenge

Osteoarthritis is a widespread global health issue, affecting more than 500 million people worldwide. In the United States, approximately 14 million people suffer from knee arthritis, while more than 5 million are affected in the UK.

Because being overweight or obese increases the load on joints, it significantly raises the risk of developing knee arthritis. Many patients eventually require surgery, with the UK alone performing over 120,000 knee replacements every year.

Did You Know? Globally, more than 500 million people live with osteoarthritis, with knee arthritis being the most common form of the condition.

Analyzing the Impact of GLP-1 Medications

Experts at the University of Maryland School of Medicine examined data from 6.8 million adults diagnosed with knee osteoarthritis between 2010 and 2024. The study, published in Regional Anesthesia & Pain Medicine, focused on the effects of GLP-1 medications.

Researchers compared a matched sample of 42,000 people who took GLP-1 medications for at least one year against a similar group who did not. They also analyzed a specific group of just under 31,000 patients who utilized the drugs for three years.

The results indicated that one year of GLP-1 medication was associated with a 1.4-percentage-point reduced risk of surgery at a three-year follow-up and a 2.8-percentage-point lower risk after eight years.

Long-Term Treatment and Potential Outcomes

The most significant risk reductions were linked to longer treatment durations and newer medications. Taking tirzepatide or semaglutide for three years was associated with a nearly 5-percentage-point lower chance of needing a knee replacement at the eight-year mark.

Based on these findings, authors speculated that if all eligible patients with obesity or metabolic disease and knee arthritis used these drugs for three years, the impact could be substantial. This could potentially lead to 14,400 fewer knee replacements annually in the US and over 1,500 fewer in the UK.

Expert Insight: Samantha Carter notes that the significance of this research lies in the possibility of “weight-independent mechanisms.” If these drugs provide anti-inflammatory and cartilage-protective benefits beyond simple weight loss, it could fundamentally change how clinicians approach the prevention of joint degradation.

Medical Perspectives and Necessary Caution

Researchers believe GLP-1 receptor agonists may influence knee health through analgesic and anti-inflammatory mechanisms. Mark Bowditch, a consultant knee surgeon, noted these drugs may have direct cartilage-protective effects.

Doctors using GLP1 to help with knee replacement surgery

However, Bowditch urged caution, stating that the findings do not prove the drugs prevent surgery. He emphasized that GLP-1 receptor agonists are not approved for treating osteoarthritis and cautioned against their use for this purpose outside of clinical trials.

Prof Lucy Donaldson of Arthritis UK added that while weight loss is vital for managing weight-bearing joints, even small amounts of weight loss can improve symptoms and may slow the progression of the disease.

What May Happen Next

Future clinical trials may be conducted to determine if GLP-1 medications can be officially approved for the treatment of osteoarthritis. This could lead to a shift in how obesity and joint pain are managed concurrently.

Healthcare providers may increasingly consider the metabolic health of patients with knee arthritis as a primary factor in delaying or avoiding surgical interventions. Longer-term treatment protocols could become a standard point of discussion for eligible patients.

Frequently Asked Questions

Which specific medications were mentioned in the research?
The research mentioned GLP-1 medications, specifically naming Mounjaro, Wegovy, and Ozempic, as well as the substances semaglutide and tirzepatide.

What was the risk reduction for those taking the drugs for three years?
Taking semaglutide or tirzepatide for three years was associated with a nearly 5-percentage-point lower chance of needing a knee replacement at the eight-year follow-up assessment.

Are these medications currently approved to treat knee arthritis?
No. Experts have stated that GLP-1 receptor agonists are not approved for the treatment of osteoarthritis and caution against using them for this purpose outside of clinical trials.

Do you believe metabolic health treatments should play a larger role in preventing joint surgeries?

Weight-loss drugs may prevent thousands of knee replacements, study suggests | Osteoarthritis